All In Biotech

Free tool

FAERS Monitor: Ultravate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208183 or its brand name (Ultravate, Halobetasol Propionate). Reports on generic versions are filed under their own applications.

Reports

1,220

Serious

441

36% of reports

Hospitalization

170

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective253
  • psoriasis167
  • pruritus113
  • product use in unapproved indication87
  • rash80
  • pain72
  • fatigue68
  • arthralgia65
  • dry skin54
  • cough51
  • off label use50
  • skin exfoliation49
  • diarrhoea48
  • nausea48
  • condition aggravated46

Reports by year received

View as table
YearReports
200423
200523
200622
200714
20084
200911
20107
201115
201219
201321
201423
201549
201677
201752
201856
201960
202071
202176
2022146
2023233
202486
202570
202662

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,939 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal16722.119.23,355
skin exfoliationSignal4910.07.6390
dry skinSignal547.05.4272
product use in unapproved indicationSignal876.14.9366
pruritusSignal1135.14.3372
drug ineffectiveSignal2533.33.0433
rashSignal803.22.6119
coughSignal513.12.473
arthralgiaSignal652.72.169
condition aggravatedSignal462.62.045
painSignal722.01.637
fatigue681.51.211
diarrhoea481.31.03
nausea481.00.80
off label use501.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.